Andrew J. Greenfield - May 25, 2021 Form 4 Insider Report for ABIOMED INC (ABMD)

Role
VP, Chief Commercial Officer
Signature
/s/ Ian W. McLeod (by power of attorney)
Stock symbol
ABMD
Transactions as of
May 25, 2021
Transactions value $
$0
Form type
4
Date filed
5/27/2021, 04:46 PM
Previous filing
May 18, 2021
Next filing
Jun 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABMD Common Stock, $.01 par value Award $0 +2K +5.53% $0.00 38.1K May 25, 2021 Direct F3
holding ABMD Common Stock, $.01 par value 12K May 25, 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABMD Stock Option (right to buy) Award $0 +2.87K $0.00 2.87K May 25, 2021 Common Stock 2.87K $283.88 Direct F1, F2
holding ABMD Stock Option (right to buy) 5K May 25, 2021 Common Stock 0 $99.62 Direct F1, F2
holding ABMD Stock Option (right to buy) 6.5K May 25, 2021 Common Stock 0 $134.51 Direct F1, F2
holding ABMD Stock Option (right to buy) 4K May 25, 2021 Common Stock 0 $381.97 Direct F1, F2
holding ABMD Stock Option (right to buy) 7K May 25, 2021 Common Stock 0 $266.39 Direct F1, F2
holding ABMD Stock Option (right to buy 4.9K May 25, 2021 Common Stock 0 $223.90 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
F2 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F3 Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25, 2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates.